About 22,000 health facilities suffer from persistent COVID-19. More than half continue to suffer after six months of discharge, and one in five is still on work leave. These are data from the union of CSIF officials that claims that the persistent coronavirus is declared an occupational disease.
The first clinical trial to treat the persistent coronavirus will be at the Germans Trias i Pujol Hospital (Can Ruti). The method consists of cleaning the blood plasma of inflammatory substances that could be behind this ailment. Spanish researchers have managed to create antibodies capable of protecting against the most virulent variants of the coronavirus. The funny thing is, they’ve done it with dromedary immune system cells. They could be used as therapy in Covid patients at higher risk.
The doctor and coordinator of the persistent covid unit in Can Ruti, Lourdes Mateu, explained to the aforementioned media that some of the theories that explain the persistent covid refer to “inflammation, autoimmunity or viral persistence”. It is for this reason that from Can Ruti want to address first “the cleaning of the plasma of inflammatory substances of these patients”, who have long had to endure symptoms identified with the pathology, such as fatigue or difficulty breathing.
The Hospital planned to start the trial this June, although it now suspects that it should be postponed until September because they do not yet have the approval of the Spanish Agency for Medicines and Medical Devices (Aemps).